Hives clinical trials at University of California Health
4 research studies open to eligible people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
open to eligible people ages 18 years and up
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
at UCLA
Barzolvolimab in Participants With Chronic Spontaneous Urticaria
open to eligible people ages 18 years and up
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
at UCLA
Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
open to eligible people ages 18 years and up
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
at UCLA
Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
open to all eligible people
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
at UC Irvine UCSD
Our lead scientists for Hives research studies include April W. Armstrong, MD, MPH Gary J. Schiller, MD Lawrence F Eichenfield, MD.
Last updated: